Fitxa

oai_dc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

   1. <dc:title>-Omic Approaches and Treatment Response in Rheumatoid Arthritis.</dc:title>

   2. <dc:creator>Madrid-Paredes, Adela</dc:creator>

   3. <dc:creator>Martín, Javier</dc:creator>

   4. <dc:creator>Márquez, Ana</dc:creator>

   5. <dc:subject>DNA methylation</dc:subject>

   6. <dc:subject>epigenomics</dc:subject>

   7. <dc:subject>genomics</dc:subject>

   8. <dc:subject>microRNAs</dc:subject>

   9. <dc:subject>proteomics</dc:subject>

   10. <dc:subject>rheumatoid arthritis</dc:subject>

   11. <dc:subject>transcriptomics</dc:subject>

   12. <dc:subject>treatment response</dc:subject>

   13. <dc:description>Rheumatoid arthritis (RA) is an inflammatory disorder characterized by an aberrant activation of innate and adaptive immune cells. There are different drugs used for the management of RA, including disease-modifying antirheumatic drugs (DMARDs). However, a significant percentage of RA patients do not initially respond to DMARDs. This interindividual variation in drug response is caused by a combination of environmental, genetic and epigenetic factors. In this sense, recent -omic studies have evidenced different molecular signatures involved in this lack of response. The aim of this review is to provide an updated overview of the potential role of -omic approaches, specifically genomics, epigenomics, transcriptomics, and proteomics, to identify molecular biomarkers to predict the clinical efficacy of therapies currently used in this disorder. Despite the great effort carried out in recent years, to date, there are still no validated biomarkers of response to the drugs currently used in RA. -Omic studies have evidenced significant differences in the molecular profiles associated with treatment response for the different drugs used in RA as well as for different cell types. Therefore, global and cell type-specific -omic studies analyzing response to the complete therapeutical arsenal used in RA, including less studied therapies, such as sarilumab and JAK inhibitors, are greatly needed.</dc:description>

   14. <dc:date>2023-05-03T14:21:29Z</dc:date>

   15. <dc:date>2023-05-03T14:21:29Z</dc:date>

   16. <dc:date>2022-08-08</dc:date>

   17. <dc:type>research article</dc:type>

   18. <dc:type>VoR</dc:type>

   19. <dc:identifier>1999-4923</dc:identifier>

   20. <dc:identifier>http://hdl.handle.net/10668/21558</dc:identifier>

   21. <dc:identifier>36015273</dc:identifier>

   22. <dc:identifier>10.3390/pharmaceutics14081648</dc:identifier>

   23. <dc:identifier>PMC9412998</dc:identifier>

   24. <dc:identifier>https://www.mdpi.com/1999-4923/14/8/1648/pdf?version=1659948899</dc:identifier>

   25. <dc:identifier>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412998/pdf</dc:identifier>

   26. <dc:language>en</dc:language>

   27. <dc:rights>Attribution 4.0 International</dc:rights>

   28. <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>

   29. <dc:rights>open access</dc:rights>

   30. <dc:format>application/pdf</dc:format>

   </oai_dc:dc>